Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?
Results of Phase II trial to assess the efficacy and safety of idelalisib
IMPACT: a UK clinical trials programme for hemonc patients post-transplant
Do immunoglobulin receptor interactions play a role in CLL?
Clinicogenetic risk models to predict outcome of follicular lymphoma patients